An Infectious Disease-Associated Il12b Polymorphism Regulates IL-12/23 p40 Transcription Involving Poly(ADP- Ribose) Polymerase 1

被引:6
|
作者
Zhao, Quanju [1 ]
Du, Qinglin [1 ]
Wei, Fang [1 ]
Xie, Jianping [2 ]
Ma, Xiaojing [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Sheng Yushou Ctr Cell Biol & Immunol, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China
[2] Southwest Univ, State Key Lab Breeding Base Ecoenvironm & Bioreso, Key Lab Ecoenvironm Three Gorges Reservoir Reg, Minist Educ,Sch Life Sci,Inst Modern Biopharmaceu, Chongqing 400715, Peoples R China
[3] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA
来源
JOURNAL OF IMMUNOLOGY | 2017年 / 198卷 / 07期
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; CEREBRAL MALARIA; GENE-EXPRESSION; PROMOTER POLYMORPHISM; BINDING; MACROPHAGES; ACTIVATION; PARP-1; CELLS; ELEMENTS;
D O I
10.4049/jimmunol.1601894
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-12 and IL-23 are important host defense factors produced by APCs against certain intracellular and extracellular pathogens. Their dysregulation has also been implicated in several autoimmune diseases. The nucleotide polymorphism in the promoter region of Il12b (rs41292470 consisting of the long or short allele) encoding the shared subunit of IL-12 and IL-23, p40, has been reported to associate with susceptibility to infectious diseases and autoimmune disorders. How these genetic variants impact Il12b expression at the molecular level was unclear. We established an Il12b promoter-luciferase reporter system containing the long or short allele driving the reporter gene expression and found that the long allele (infection-resistant) displayed-2-fold higher transcriptional activity than the short allele (infection-susceptible), associated with a selective and differential nuclear binding activity to the two alleles in activated macrophages. DNA pull-down assays coupled with mass spectrometry analyses identified the specific DNA binding activity as poly(ADP-ribose) polymerase 1 (PARP-1). Small hairpin RNA-mediated knockdown of the endogenous PARP-1 expression resulted in reduced p40 mRNA expression and Il12b promoter activity. Bone marrow-derived macrophages from PARP-1-deficient mice had decreased p40 expression at both mRNA and protein levels. Furthermore, selective PARP-1 inhibitors resulted in impaired production of IL-12p40 and IL-23 in bone-marrow derived macrophages and PBMCs. Chromatin immunoprecipitation assay revealed that PARP-1 could bind specifically to Il12b in LPS-stimulated macrophages. Our study opens the way for further elucidating the molecular mechanism whereby allele-specific immune responses to foreign and selfantigens mediated by IL-12/ IL-23 are controlled in an individually variable manner.
引用
收藏
页码:2935 / 2942
页数:8
相关论文
共 49 条
  • [41] IL-12/IL-23 P40 Peptide-Based Vaccine Ameliorates TNBS-Induced Murine Chronic Colitis By Down-Regulation of TH1 and TH17 Cytokines
    Guan, Qingdong
    Ma, Yangbing
    Ma, Allan
    Zhou, Gang
    Hillman, China-Li
    Weiss, Carolyn R.
    Qing, Gefei
    Peng, Zhikang
    GASTROENTEROLOGY, 2009, 136 (05) : A255 - A255
  • [42] An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis
    Javan, Mohammad Reza
    Shahraki, Sarieh
    Safa, Amin
    Zamani, Mohammad Reza
    Salmaninejad, Arash
    Aslani, Saeed
    NEUROLOGICAL RESEARCH, 2017, 39 (05) : 435 - 441
  • [43] The Septic Shock-Associated IL-10-1082 A > G Polymorphism Mediates Allele-Specific Transcription via Poly(ADP-Ribose) Polymerase 1 in Macrophages Engulfing Apoptotic Cells
    Kang, Xiaoyan
    Kim, Ha-Jeong
    Ramirez, Michelle
    Salameh, Sarah
    Ma, Xiaojing
    JOURNAL OF IMMUNOLOGY, 2010, 184 (07): : 3718 - 3724
  • [44] Regulation of IL-12 p40 promoter activity in primary human monocytes:: Roles of NF-κB, CCAAT/enhancer-binding protein β, and PU.1 and identification of a novel repressor element (GA-12) that responds to IL-4 and prostaglandin E2
    Becker, C
    Wirtz, S
    Ma, XJ
    Blessing, M
    Galle, PR
    Neurath, MF
    JOURNAL OF IMMUNOLOGY, 2001, 167 (05): : 2608 - 2618
  • [45] A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1
    Sandborn, William
    Gasink, Christopher
    Blank, Marion
    Lang, Yinghua
    Johanns, Jewel
    Gao, Long-Long
    Sands, Bruce
    Hanauer, Stephen
    Feagan, Brian
    Targan, Stephan
    Ghosh, Subrata
    de Villiers, Wim
    Colombel, Jean-Frederic
    Lee, Scott
    Desreumaux, Pierre
    Loftus, Edward, Jr.
    Vermeire, Severine
    Rutgeerts, Paul
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S1 - S1
  • [46] 烫伤对小鼠腹腔巨噬细胞LPS/Toll信号通路的影响——c-fos基因表达、AP-1和NF-кB的DNA结合活性及IL-12 p40基因表达的抑制
    王兴宇
    张劲松
    苏踊跃
    李昌麟
    冯卫国
    张宗梁
    中国科学(C辑:生命科学), 2002, (03) : 256 - 263
  • [47] A MULTICENTER, DOUBLE-BLIND, PLACEBO (PBO)CONTROLLED PH3 STUDY OF USTEKINUMAB (UST), A HUMAN IL-12/23P40 MAB, IN MODERATE-SEVERE CROHN'S DISEASE (CD) REFRACTORY TO ANTI-TNFA: UNITI-1
    Rutgeerts, P.
    Gasink, C.
    Blank, M.
    Lang, Y.
    Johanns, J.
    Gao, L-L
    Sands, B.
    Hanauer, S.
    Feagan, B.
    Targan, S.
    Ghosh, S.
    de Villiers, W.
    Colombel, J-F
    Lee, S. D.
    Desreumaux, P.
    Loftus, E. V.
    Vermeire, S.
    Sandborn, W. J.
    GUT, 2016, 65 : A3 - A4
  • [48] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study or Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial
    Sandborn, William J.
    Gasink, Christopher
    Gao, Long-Long
    Blank, Marion
    Johanns, Jewel
    Guzzo, Cynthia
    Sands, Bruce E.
    Hanauer, Stephen B.
    Targan, Stephan R.
    Rutgeerts, Paul J.
    Ghosh, Subrata
    de Villiers, Willem
    Panaccione, Remo
    Greenberg, Gordon R.
    Schreiber, Stefan
    Lichtiger, Simon
    Feagan, Brian G.
    GASTROENTEROLOGY, 2011, 140 (05) : S109 - S109
  • [49] A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohn's Disease: Results through Week 36 from the CERTIFI Trial
    Feagan, Brian
    Gasink, C.
    Gao, L.
    Blank, M.
    Johanns, J.
    Guzzo, C.
    Sands, B.
    Hanauer, Stephen
    Targan, S.
    Rutgeerts, P.
    Ghosh, S.
    de Villiers, W.
    Panaccione, R.
    Greenberg, G.
    Schreiber, S.
    Lichtiger, S.
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S463 - S463